查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600542

雙特異性抗體市場：按作用機制、治療領域和最終用戶 - 2025-2030 年全球預測

Bispecific Antibodies Market by Mechanism of Action (Dual Antigen Targeting, Dual-Blocking Antibodies, T-cell Engagers), Therapeutic Area (Autoimmune Diseases, Infectious Diseases, Neurological Disorders), End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年雙特異性抗體市值為57.1億美元，預計2024年將達到74.9億美元，複合年成長率為32.64%，2030年將達到412.9億美元。

雙特異性抗體是一種工程蛋白，可以同時結合兩種不同類型的抗原，使其成為免疫療法和癌症治療領域的重要創新。與單株抗體相比，它們有可能提高治療效果並減少抗藥性細菌。對雙特異性抗體的需求源於其改善治療特異性和結果的能力，特別是在腫瘤學和自體免疫疾病方面。其應用不僅限於癌症，在感染疾病和發炎疾病方面也具有潛力。最終用途包括醫院、研究機構和製藥業，以利用獨特的功能來改善患者的治療效果。關鍵的成長要素包括目標疾病盛行率的增加、基因工程的進步以及為增強治療應用而增加的研發投資。正在進行的臨床試驗和監管核准正在推動對個人化醫療的需求。然而，製造複雜性、高開發成本、潛在副作用和嚴格的監管要求為市場成長帶來了挑戰。最新的商機凸顯了市場對生物相似藥和具有成本效益的製造方法不斷成長的需求。鼓勵企業探索臨床試驗合作，利用CRISPR技術最佳化抗體特性，並專注於下一代雙特異性抗體平台。創新的關鍵領域包括提高標靶準確性、最大限度地減少脫靶效應以及開發超越雙特異性的多特異性抗體。人工智慧和巨量資料分析的更多使用可能會徹底改變開發過程，從而實現患者分層和治療客製化。儘管當前的進步使市場充滿希望，但克服成本和複雜性問題對於進一步成長至關重要。快速的技術進步塑造了競爭格局，需要持續創新和策略夥伴關係，以保持競爭力並有效解決未滿足的需求。

主要市場統計
基準年[2023] 57.1億美元
預測年份 [2024] 74.9億美元
預測年份 [2030] 412.9億美元
複合年成長率（%） 32.64%

市場動態：揭示快速發展的雙特異性抗體市場的關鍵市場洞察

雙特異性抗體市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球感染疾病和慢性病的增加
    • 基因和蛋白質工程技術的進展
    • 增加對新型雙特異性抗體的開發和核准的監管支持
  • 市場限制因素
    • 生產雙特異性抗體的複雜性
  • 市場機會
    • 個人化治療方法的新興趨勢
    • 擴大雙特異性抗體在罕見疾病治療的應用
  • 市場挑戰
    • 雙特異性抗體的安全性和有效性所面臨的挑戰

波特五力：駕馭雙特異性抗體市場的策略工具

波特的五力框架是了解雙特異性抗體市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，並確保更強大的市場定位。

市場佔有率分析 了解雙特異性抗體市場的競爭格局

雙特異性抗體市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣雙特異性抗體市場供應商績效評估

FPNV定位矩陣是評估雙特異性抗體市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製雙特異性抗體市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對雙特異性抗體市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球感染疾病和慢性病的發生率正在上升
      • 基因工程和蛋白質工程技術進展
      • 擴大對新型雙特異性抗體的開發和核准的監管支持
    • 抑制因素
      • 生產雙特異性抗體的複雜性
    • 機會
      • 個人化治療方法的新興趨勢
      • 擴大雙特異性抗體在罕見疾病治療的應用
    • 任務
      • 與雙特異性抗體的安全性和有效性相關的問題
  • 市場區隔分析
    • 作用機轉：雙抗原標靶化優先以最大限度地減少脫靶效應
    • 治療領域：擴大雙特異性抗體在腫瘤學的應用，攻擊並破壞癌細胞
    • 最終使用者：在醫院和專科診所提供全面的治療護理
  • 波特五力分析

第6章依作用機轉分類的雙特異性抗體市場

  • 雙抗原靶點
  • 雙抑制抗體
  • T 細胞接合器

第7章依治療領域分類的雙特異性抗體市場

  • 自體免疫疾病
  • 感染疾病
  • 神經系統疾病
  • 腫瘤學

第 8 章雙特異性抗體市場：依最終用戶分類

  • 醫院和專家
  • 研究機構和學術中心

第9章美洲雙特異性抗體市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太雙特異性抗體市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲雙特異性抗體市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 默克公司收購針對 B 細胞惡性的新型雙特異性抗體，擴大腫瘤學產品組合
    • 諾華與 Dren Bio 合作開發創新雙特異性抗體，徹底改變癌症治療
    • 強生公司收購 Numab Therapeutics 加強雙特異性抗體產品線
    • Regeneron 強調新型雙特異性抗體 REGN7075 具有良好的抗腫瘤活性
    • Zenas Biopharma 籌集 2 億美元 C 輪資金籌措
    • Invenra與Astellas來結成策略聯盟，利用B-Body平台加強雙特異性抗體研發
    • Biotheus 和 Hansoh Pharma 擴大合作夥伴關係，開發用於癌症治療的創新雙特異性抗體藥物複合體
    • FDA核准強生公司的 TECVAYLI 用於每兩週治療多發性骨髓瘤
    • Astra Zeneca利用多種腫瘤抗原的創新雙特異性抗體來推進癌症治療
    • 楊森的 TALVEY talketamab-TGV 獲得 FDA 加速核准
    • FDA核准艾伯維 (AbbVie) 和 Genmab 的 EPKINLY 用於治療復發或難治性 DLBCL
    • 輝瑞的 erlanatamab 因良好的試驗結果而獲得美國FDA 和 EMA 的優先審查
  • 戰略分析和建議
    • 艾伯維公司
    • Astra Zeneca
    • F.霍夫曼羅氏有限公司
    • 安進公司

公司名單

  • AbbVie Inc.
  • Adimab, LLC
  • Affimed GmbH
  • Alligator Bioscience AB
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • Innovent Biologics, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Mereo Biopharma Group PLC
  • Merus NV
  • Novartis AG
  • Pfizer Inc.
  • Pieris Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
  • TG Therapeutics, Inc.
  • Xencor, Inc.
Product Code: MRR-F97DD5A7DF65

The Bispecific Antibodies Market was valued at USD 5.71 billion in 2023, expected to reach USD 7.49 billion in 2024, and is projected to grow at a CAGR of 32.64%, to USD 41.29 billion by 2030.

Bispecific antibodies are engineered proteins that can simultaneously bind to two different types of antigens, making them a vital innovation in the field of immunotherapy and cancer treatment. Their scope is significant as they provide a means to target multiple pathways in diseases, potentially enhancing therapeutic efficacy and reducing resistance compared to monoclonal antibodies. The necessity for bispecific antibodies stems from their ability to improve treatment specificities and outcomes, especially in oncology and autoimmune diseases. The application extends beyond cancer, with potential in infectious diseases and inflammatory conditions. The end-use scope involves hospitals, research institutes, and pharmaceutical industries, leveraging their unique capabilities for better patient outcomes. Key growth factors include an increasing incidence of target diseases, advancements in genetic engineering, and expanding R&D investments aimed at enhancing therapeutic applications. Demand is bolstered by ongoing clinical trials and regulatory approvals, placing emphasis on personalized medicine. However, market growth is challenged by the complexity in manufacturing, high cost of development, potential side effects, and stringent regulatory requirements. Latest opportunities reveal an emerging market need for biosimilars and cost-effective production methods. Companies are encouraged to explore collaborations for clinical trials, harness CRISPR technology to optimize antibody properties, and focus on next-generation bispecific antibody platforms. Areas prime for innovation include enhancing targeting precision, minimizing off-target effects, and developing multi-specific antibodies beyond the bispecific framework. Increased use of artificial intelligence and big data analytics can revolutionize development processes, leading to better patient stratification and treatment customization. While the market shows promise with current advancements, navigating cost and complexity issues remains essential for further growth. The competitive environment is shaped by rapid technological progress, necessitating continuous innovation and strategic partnerships to maintain a competitive edge and address unmet clinical needs effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 5.71 billion
Estimated Year [2024] USD 7.49 billion
Forecast Year [2030] USD 41.29 billion
CAGR (%) 32.64%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bispecific Antibodies Market

The Bispecific Antibodies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of infectious and chronic illnesses globally
    • Advancements in genetic engineering and protein engineering technologies
    • Growing regulatory support for the development and approval of novel bispecific antibodies
  • Market Restraints
    • Complexities in the manufacturing of bispecific antibodies
  • Market Opportunities
    • Emerging trend toward personalized therapeutic approaches
    • Expanding usage of bispecific antibodies in the treatment of rare diseases
  • Market Challenges
    • Issues associated with the safety and efficacy of bispecific antibodies

Porter's Five Forces: A Strategic Tool for Navigating the Bispecific Antibodies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bispecific Antibodies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

Market Share Analysis: Understanding the Competitive Landscape in the Bispecific Antibodies Market

A detailed market share analysis in the Bispecific Antibodies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bispecific Antibodies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bispecific Antibodies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bispecific Antibodies Market

A strategic analysis of the Bispecific Antibodies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bispecific Antibodies Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adimab, LLC, Affimed GmbH, Alligator Bioscience AB, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche Ltd., Genmab A/S, Gilead Sciences, Inc., Innovent Biologics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Mereo Biopharma Group PLC, Merus N.V., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., TG Therapeutics, Inc., and Xencor, Inc..

Market Segmentation & Coverage

This research report categorizes the Bispecific Antibodies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Mechanism of Action, market is studied across Dual Antigen Targeting, Dual-Blocking Antibodies, and T-cell Engagers.
  • Based on Therapeutic Area, market is studied across Autoimmune Diseases, Infectious Diseases, Neurological Disorders, and Oncology.
  • Based on End-user, market is studied across Hospitals & Specialist Clinics and Research Institutions & Academic Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, Michigan, Montana, New York, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of infectious and chronic illnesses globally
      • 5.1.1.2. Advancements in genetic engineering and protein engineering technologies
      • 5.1.1.3. Growing regulatory support for the development and approval of novel bispecific antibodies
    • 5.1.2. Restraints
      • 5.1.2.1. Complexities in the manufacturing of bispecific antibodies
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging trend toward personalized therapeutic approaches
      • 5.1.3.2. Expanding usage of bispecific antibodies in the treatment of rare diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Issues associated with the safety and efficacy of bispecific antibodies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Mechanism of Action: Increasing preference for dual antigen targeting for minimizing off-target effects
    • 5.2.2. Therapeutic Area: Expanding application of bispecific antibodies in oncology for engaging and destroying cancer cells
    • 5.2.3. End-user: Provision of comprehensive therapeutic care in hospitals and specialist clinics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Bispecific Antibodies Market, by Mechanism of Action

  • 6.1. Introduction
  • 6.2. Dual Antigen Targeting
  • 6.3. Dual-Blocking Antibodies
  • 6.4. T-cell Engagers

7. Bispecific Antibodies Market, by Therapeutic Area

  • 7.1. Introduction
  • 7.2. Autoimmune Diseases
  • 7.3. Infectious Diseases
  • 7.4. Neurological Disorders
  • 7.5. Oncology

8. Bispecific Antibodies Market, by End-user

  • 8.1. Introduction
  • 8.2. Hospitals & Specialist Clinics
  • 8.3. Research Institutions & Academic Centers

9. Americas Bispecific Antibodies Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bispecific Antibodies Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bispecific Antibodies Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Merck & Co Inc expands oncology portfolio with acquisition of novel bispecific antibody for B-cell malignancies
    • 12.3.2. Novartis collaborates with Dren Bio, for innovative bispecific antibodies to revolutionize cancer treatments
    • 12.3.3. Johnson & Johnson's Acquisition of Numab Therapeutics Boosting Bispecific Antibody Pipeline
    • 12.3.4. Regeneron highlights promising anti-tumor activity of novel bispecific antibody REGN7075
    • 12.3.5. Zenas Biopharma raises USD 200 Million in Series C Funding
    • 12.3.6. Invenra and Astellas Pharma form strategic partnership to enhance bispecific antibody R&D using the B-Body platform
    • 12.3.7. Biotheus and Hansoh Pharma expand partnership to develop innovative bispecific antibody-drug conjugates for cancer treatment
    • 12.3.8. FDA approves Johnson & Johnson's TECVAYLI for biweekly dosing in multiple myeloma
    • 12.3.9. AstraZeneca advances cancer treatment with innovative bispecific antibodies targeting multiple tumor antigens
    • 12.3.10. Janssen's TALVEY talquetamab-tgvs receives FDA accelerated approval
    • 12.3.11. FDA greenlights AbbVie and Genmab's EPKINLY for relapsed or refractory DLBCL
    • 12.3.12. Pfizer's elranatamab receives priority review by US FDA and EMA with positive trial results
  • 12.4. Strategy Analysis & Recommendation
    • 12.4.1. AbbVie Inc.
    • 12.4.2. AstraZeneca PLC
    • 12.4.3. F. Hoffmann-La Roche Ltd.
    • 12.4.4. Amgen Inc.

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adimab, LLC
  • 3. Affimed GmbH
  • 4. Alligator Bioscience AB
  • 5. Amgen Inc.
  • 6. Astellas Pharma Inc.
  • 7. AstraZeneca PLC
  • 8. Bristol-Myers Squibb
  • 9. Eli Lilly and Company
  • 10. Emergent BioSolutions Inc.
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. Genmab A/S
  • 13. Gilead Sciences, Inc.
  • 14. Innovent Biologics, Inc.
  • 15. Johnson & Johnson Services, Inc.
  • 16. Merck KGaA
  • 17. Mereo Biopharma Group PLC
  • 18. Merus N.V.
  • 19. Novartis AG
  • 20. Pfizer Inc.
  • 21. Pieris Pharmaceuticals, Inc.
  • 22. Regeneron Pharmaceuticals Inc.
  • 23. Sanofi S.A.
  • 24. TG Therapeutics, Inc.
  • 25. Xencor, Inc.

LIST OF FIGURES

  • FIGURE 1. BISPECIFIC ANTIBODIES MARKET RESEARCH PROCESS
  • FIGURE 2. BISPECIFIC ANTIBODIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BISPECIFIC ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BISPECIFIC ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BISPECIFIC ANTIBODIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BISPECIFIC ANTIBODIES MARKET DYNAMICS
  • TABLE 7. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL ANTIGEN TARGETING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL-BLOCKING ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY T-CELL ENGAGERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY HOSPITALS & SPECIALIST CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. BISPECIFIC ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. BISPECIFIC ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023